BHVN NYSE Week ended 24 Jul 2026

Weekly Investor Report

Biohaven Ltd. · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 14.32 USD
-7.3% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 24.8% above the Trend Line and sits at 61.7% of its 52-week range. The latest completed week returned -7.3%, after a -9.5% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 45/100 conviction, while the latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 44 out of 100
Latest Close 14.32 USD 24 Jul 2026
1W Return -7.3% latest completed week
4W Return -9.5% short-term follow-through
12W Return 48.7% quarterly tape
Trend Breadth 9.6% 5 of 52 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • The trend backdrop is active with a 5-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • The share remains more than 20% below its 52-week high.
  • The latest week was a sharp negative move.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -7.3% Latest completed week; four-week move -9.5%. Indicator stack 23/72 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 45/100 conviction; expected move 17.6%. News sentiment 53/100 64 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 24.8% above the Trend Line and sits at 61.7% of its 52-week range. The latest completed week returned -7.3%, after a -9.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5012-week average 0.19

12-week confirmation

Trend active5/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership5/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.50Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -9.5% over four weeks, 48.7% over 12 weeks, and 6.1% over one year. The current trend has remained active for 5 consecutive weeks.

Performance by holding period

1W-7.3%
4W-9.5%
12W48.7%
26W6.0%
52W6.1%
Active trend streak5 weeks
Active weeks in one year5
Trend breadth9.6%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.35Latest activity-pressure read.
Pressure change-27.2%Four-week change in activity pressure.
Leadership7.32Latest relative-leadership reading.
RS change-61.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength26/100Blend of value, momentum, and quality. Underlying universe rank 75; rank 1 is best.
Value39/100Relative valuation strength. Underlying universe rank 62; rank 1 is best.
Quality38/100Profitability and accounting quality. Underlying universe rank 63; rank 1 is best.
Momentum40/100Medium-term price momentum. Underlying universe rank 61; rank 1 is best.
Growth40/100Revenue and earnings growth. Underlying universe rank 61; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-27.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-340.1%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-17.1%
Net share repurchases relative to market value.
Shareholder yield
-17.1%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

BHVN shows volatility options pressure with a 45/100 conviction score, put-call volume ratio of 1.82, expected move of 17.6%, and Sharemaestro trend signal active.

Conviction45/100
Expected move17.6%
Put/call volume1.82
Pressure-20
Speculation37
Volatility96
Trend agreement73
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment53/100

Weighted news tone is neutral across 64 relevant articles.

12 positive · 46 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
Options expected move17.6%Nearest-chain priced movement where available.
52-week drawdown-22.9%Distance below the 52-week high.
13-week volatility9.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2616 weeks finished lower.
Best week+20.3%Week of 19 Jun.
Worst week-13.9%Week of 6 Mar.
Latest week-7.3%Week of 24 Jul.

Shape of recent returns

Strong gains7
Modest gains3
Flat weeks0
Modest losses8
Sharp losses8
Recent vol9.2%13-week weekly-return volatility.
Base vol11.4%52-week weekly-return volatility.
Up/down split28/24Count of positive and negative weeks in the 52-week window.
Average skew7.7% / -7.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape41/100

Trend, activity pressure, participation, and risk combine to a 41/100 tape read.

 Indicator analysis52/100

Latest 12-week confirmation: trend 5/12, activity pressure 9/12, relative leadership 5/12.

Activity pressure 0.50; No reversal markers Factors34/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 90; Small Cap Core rank 61 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options54/100

BHVN shows volatility options pressure with a 45/100 conviction score, put-call volume ratio of 1.82, expected move of 17.6%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 17.6% Sentiment53/100

Weighted news tone is neutral across 64 relevant articles.

Why is Biohaven Pharmaceutical stock gaining today? Insiders50/100

No recent insider transaction evidence is stored.

 Earnings11d

Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202614.32 USD-7.3%11.47 USD27.16 USD1.357.329.0MOn
17 Jul 202615.44 USD-0.7%11.37 USD27.19 USD1.6814.789.3MOn
10 Jul 202615.55 USD-2.6%11.22 USD27.25 USD1.8913.5912.9MOn
3 Jul 202615.96 USD0.8%11.08 USD27.31 USD1.9717.9314.9MOn
26 Jun 202615.83 USD16.7%10.87 USD27.35 USD1.8619.2226.1MOn
19 Jun 202613.57 USD20.3%10.67 USD27.40 USD1.66-0.3820.3MOff
12 Jun 202611.28 USD4.4%10.55 USD27.46 USD1.15-16.9916.7MOff
5 Jun 202610.80 USD-1.9%10.45 USD27.54 USD0.60-20.9813.6MOff
29 May 202611.01 USD16.5%10.36 USD27.63 USD0.27-22.5916.4MOff
22 May 20269.45 USD7.9%10.57 USD27.70 USD-0.19-33.3310.1MOff
15 May 20268.76 USD-11.2%10.81 USD27.74 USD-0.29-38.579.8MOff
8 May 20269.86 USD2.4%11.05 USD27.77 USD-0.16-31.7611.1MOff
1 May 20269.63 USD-2.5%11.24 USD27.79 USD-0.31-33.287.4MOff
24 Apr 20269.88 USD-10.0%11.45 USD27.82 USD-0.21-32.688.6MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.